EXCLUSIVE: Elon Musk Reclaims Ownership of Gene Wilder Home in L.A.—After Foreclosing on Actor's Nephew Over $7 Million Loan
Tesla billionaire Elon Musk has returned an iconic Los Angeles property to his growing real estate collection—after reclaiming ownership of a historic dwelling that was once home to 'Charlie and the Chocolate Factory' star Gene Wilder.
Months after it was revealed that Musk had moved to foreclose on the former owners of the dwelling—whom he had lent the money to buy it from him—property records reveal that ownership has been transferred back to the LLC through which the SpaceX founder originally purchased it.
Musk, 53, first bought the three-bedroom dwelling for $6.75 million in 2013. However, he made a move to offload the property in 2020, when he announced plans to sell 'almost all his physical possessions,' including Wilder's former home.
Still, the SpaceX founder made clear his enduring connection to the property, writing in a post shared on X that, while he planned to 'own no house,' any person or persons who took ownership of the Wilder property would be barred from demolishing it or making any major changes to its design.
'Gene Wilder's old house … cannot be [torn] down or lose any [of] its soul,' he stipulated.
Months later, it was revealed that Musk had found the perfect person to take control of the dwelling—Wilder's own nephew, Jordan Walker-Pearlman. Walker-Pearlman and his wife, Elizabeth Hunter, purchased the home from the businessman for $7 million that same year.
At the time, Musk was hailed for his generosity after it was reported that he had not only sold the home to the couple for under its estimated market value, but had also loaned them a hefty $6.7 million to help them with its purchase.
However, that seemingly sweet scenario quickly turned sour four years later, when Walker-Pearlman and Hunter fell behind on their loan payments, leading to Musk filing a notice of default.
That original default notice, which was dated July 29, 2024, stated that the property 'may be sold without court action' if the owners had fallen behind in their payments.
At the same time, Walker-Pearlman and Hunter tried to offload the home themselves, before it could be put up for auction, initially listing it for $12.95 million the following month. That price was quickly slashed to $9.5 million in November 2024.
That same month, a notice of trustee's sale under deed of trust was filed—informing Walker-Pearlman and Hunter that the dwelling would be sold at a public auction on Dec. 3, 2024.
It noted that the unpaid balance of the loan, as well as 'reasonable estimated costs, expenses, and advances,' was set at $7,512,523.10.
The auction was scheduled to take place 'behind the fountain located in Civic Center Plaza' in Pomona, CA, with bidders warned that the property was being sold subject to a restrictive covenant that prevents the home from being demolished or razed.
It is unclear whether the auction was attended by other bidders; however, a trustee's deed upon sale that was filed in January 2025 indicates that the property was purchased by the same LLC through which Musk originally purchased the home. Records indicate that the full unpaid debt paid by the buyer came to $7,587,143.06.
The home was officially taken off the market in February 2025.
It's not currently known what Musk plans to do with the property—having seemingly purchased it the first time around more as a trophy home than an actual residence.
Since selling off many of his properties in 2020, Musk has become increasingly secretive about his real estate deals. However, multiple reports have suggested that he's amassed quite an impressive collection of homes in and around Austin, TX, where Tesla is based.
The only home that Musk has publicly confirmed he lives in is a quaint ranch-style dwelling in the Brownsville, TX, neighborhood of Boca Chica, which is located mere steps away from the SpaceX headquarters and which he claimed in 2021 that he was renting from his own company.
'My primary home is literally a ~$50K house in Boca Chica/Starbase that I rent from SpaceX. It's kinda awesome though,' he wrote in a post on X.
However, in 2025, it was revealed that Musk had purchased a $6 million mansion in the upscale Austin neighborhood of West Lake Hills in 2022—after neighbors began complaining about the chaos that was being caused by his presence in the community.
According to the New York Times, multiple complaints were filed by locals over an unauthorized 16-foot chain-link fence that had been erected around the home, for which Musk and his team had failed to obtain permits.
The outlet reports that the erection of the fence and gate violated six city ordinances.
Another complaint, lodged via a letter sent to the Zoning and Planning Commission by local resident Paul Hemmer, stated that the comings and goings at the Musk property were wreaking havoc on their otherwise 'quiet streets.'
'Transporting service employees to other houses, leaving their cars on our quiet streets, hauling laundry to and fro to other houses has to stop,' he wrote.
The Times also reported that Musk had since purchased two other properties in the same area to create a 'compound' in which to house many of his children and their mothers.
Musk is alleged to have fathered 14 children by four different women in the past 20 years—although he is estranged from at least one of them.
He welcomed his first child, son Alexander, with then-wife Justin Wilson in 2002. Sadly, the baby died at just 10 weeks of age from sudden infant death syndrome.
Musk and Wilson went on to welcome five more kids: transgender daughter Vivian, from whom Musk is estranged, and her twin, Griffin; and triplets Saxon, Damian, and Kai.
From 2020 to 2022, he welcomed three children with the singer Grimes, whose real name is Claire Boucher: X Æ A-Xii, who is known as X; Exa Dark Sideræl, who is known as Y; and Techno Mechanicus, who goes by Tau.
During that same time, he also fathered twins with Shivon Zilis, an executive at his Neuralink company, with whom he now shares four children: twins Strider and Azure, born in 2021; daughter Arcadia, born in 2024; and son Seldon Lycrugus, whose birth date is not known.
In February 2025—the same month that Musk and Zilis announced the news about their fourth child—a conservative influencer named Ashley St. Clair came forward to claim that she had also welcomed a child with the billionaire, a son named Romulus.
Musk has never publicly confirmed he is the father of the child, although he stated in a post on X that he had agreed to give St. Clair $2.5 million, as well as annual payments of $500,000—although she later claimed that he had withdrawn that child support to 'punish' her for going public with the birth.
What Happens If I Stop Paying My Mortgage?
Giving or Receiving a Down Payment Gift? Here Are the Tax Consequences
How To Get a Mortgage With Bad Credit (Yes, You Can)
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Angelina Jolie Has Some Thoughts on Brad Pitt's AA Meeting Reveal, Says ‘Source'
recently shared his experience about his AA meetings post-divorce with Angelina Jolie. The 'F1' star appeared on the latest episode of the 'Armchair Expert' podcast, where he told Dax Shepard about his time with Alcoholics Anonymous. However, a source claimed that his ex-wife allegedly has some thoughts about the interview. Reportedly, Pitt's confession felt like a 'PR' to her. Brad Pitt opened up about his 'difficult time' when he hit rock bottom after his separation from Angelina Jolie. In an interview with Dax Shepard on the 'Armchair Expert' podcast, he revealed that he was on his 'knees' during his journey to become sober. Further, he shared his experience during his AA (Alcoholics Anonymous) meetings. While fans sympathized with Pitt's confession, his ex-wife might not think the same. According to ShuterScoop, a source said, 'To her, it feels like PR — not personal growth.' It seemed she was not buying her ex-husband's story and 'doesn't think a podcast fixes everything.' 'Brad's version plays well to the public, but behind the scenes, it's still a mess,' the insider added. In the podcast interview, the 'Fight Club' star stated that he was trying everything his well-wishers recommended. He confessed that he 'needed rebooting.' 'I needed to wake the f—— up in some areas. And it just meant a lot to me,' Pitt told Shepard. The 'Mr. & Mrs. Smith' co-stars tied the knot in 2016. After two years, Jolie filed for divorce, which was finalized in December 2024. They went through an eight-year-long legal battle, fighting over their custody of six kids — Maddox, Pax, Zahara, Shiloh, and twins Vivienne and Knox. Later, the mother won custody, followed by a rocky relationship between Pitt and the children. Over time, several sources claimed that the 61-year-old actor blamed Jolie for their kids' behaviour. Meanwhile, Pitt is currently dating jewelry designer Ines de Ramon. Originally reported by Sushmita Sen on Reality Tea. The post Angelina Jolie Has Some Thoughts on Brad Pitt's AA Meeting Reveal, Says 'Source' appeared first on Mandatory.
Yahoo
11 minutes ago
- Yahoo
Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation
Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan drug for the investigational use in chronic inflammatory demyelinating polyneuropathy in the US and EU Paris, June 25, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation. This designation reflects Sanofi's commitment to addressing a critical unmet need in transplant medicine, where AMR remains a significant challenge with no FDA-approved treatments available. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. Global Therapeutic Area Development Head, Immunology and Inflammation, Sanofi"Orphan drug designation for riliprubart marks an important milestone in our mission to address critical challenges in transplant medicine leveraging our expertise in immunology. Antibody mediated rejection represents a serious threat to transplanted organs and patient survival. Through riliprubart's innovative mechanism of action, we hope to bring forward a treatment option that could significantly improve outcomes for kidney transplant recipients." Riliprubart is currently being explored in multiple clinical studies across different indications in transplant and neurology. A phase 2 clinical study is currently ongoing, exploring its potential in kidney transplant recipients (NCT05156710). The study includes two patient cohorts: those at risk of developing rejection and those with active forms of antibody-mediated rejection. In addition, Sanofi is conducting two phase 3 studies exploring riliprubart in chronic inflammatory demyelinating polyneuropathy (CIPD), a rare neurological disorder, specifically in patients refractory to standard of care (MOBILIZE, clinical study identifier: NCT06290128), and in IVIg-treated patients (VITALIZE, clinical study identifier: NCT06290141). The broad clinical development program for riliprubart emphasizes Sanofi's commitment to exploring riliprubart's potential across multiple immune-mediated conditions with high unmet medical needs. About Riliprubart SAR445088 (riliprubart) is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. Riliprubart is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. For more information on riliprubart clinical studies, please visit About AMRAntibody-mediated rejection is a serious complication that may arise after solid organ transplantation, occurring when the recipient's immune system produces antibodies that attack the transplanted organ. Sensitized recipients, who have pre-existing antibodies that target foreign antigens including those found on transplanted organs, face a high risk of developing antibody-mediated rejection. Subsequent immune response can lead to inflammation, organ damage, and organ failure if left untreated. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Evan Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Léa Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen | +44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Felix Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Nathalie Pham | +33 7 85 93 30 17 | Tarik Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. Attachment Press Release
Yahoo
12 minutes ago
- Yahoo
Truist Lowers GitLab (GTLB) PT to $75, Maintains Buy Rating
GitLab Inc. (NASDAQ:) is one of the best technology stocks according to Wall Street analysts. Earlier on June 12, Truist adjusted the price target for GitLab to $75 from $80, while maintaining a Buy rating on the shares. This revision comes after GitLab's Q1 2025 results, which, although exceeding guidance, did not meet investor expectations for a larger beat. In Q1, the company reported a total revenue of $169.2 million, which marked a 33% increase year-over-year. GitLab also generated positive cash flow for the first time in a first quarter. The subscription revenue from self-managed and SaaS grew to $151.179 million from $111.191 million year-over-year, and license revenue from self-managed and other increased to $18.008 million from $15.687 million. A team of software engineers working together in an open office, developing innovative solutions. The company's customer base also expanded, with customers contributing over $5,000 of ARR, reaching 8,976, which showed a 21% increase year-over-year. Customers with over $100,000 of ARR grew by 35% year-over-year, totaling 1,025. In this quarter, GitLab also received the 2024 Google Cloud Technology Partner of the Year Award in the Application Development – DevOps category. GitLab Inc. (NASDAQ:GTLB) develops software for the software development lifecycle in the US, Europe, and the Asia Pacific. While we acknowledge the potential of GTLB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data